The most potent and broad HIV envelope (Env)-specific antibodies often when reverted to their inferred germline versions representing the naive B cell receptor, fail to bind Env, suggesting that the initial responding B cell population not only exclusively comprises a naive population, but also a pre-existing cross-reactive antigen-experienced B cell pool that expands following Env exposure. Previously we isolated gp120-reactive monoclonal antibodies (mAbs) from participants in HVTN 105, an HIV vaccine trial. Using deep sequencing, focused on immunoglobulin G (IgG), IgA, and IgM, VH-lineage tracking, we identified four of these mAb lineages in pre-immune peripheral blood. We also looked through the ∼7 month postvaccination bone marrow, and interestingly, several of these lineages that were found in prevaccination blood were still persistent in the postvaccination bone marrow, including the CD138+ long-lived plasma cell compartment. The majority of the pre-immune lineage members included IgM, however, IgG and IgA members were also prevalent and exhibited somatic hypermutation. These results suggest that vaccine-induced gp120-specific antibody lineages originate from both naive and cross-reactive memory B cells.
ClinicalTrials.gov NCT02207920
Get full access to this article
View all access options for this article.
References
1.
WHO. WHO HIV/AIDS Data and Statistics. 2019. Available from: https://www.who.int/hiv/data/en [Last accessed: June30, 2022].
2.
HaynesBF, GilbertPB, McElrathMJ, et al.Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 2012; 366(14):1275–1286; doi: 10.1056/NEJMoa1113425
3.
ChungAW, KumarMP, ArnoldKB, et al.Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell, 2015; 163(4):988–998; doi: 10.1016/j.cell.2015.10.027
4.
Zolla-PaznerS, deCampA, GilbertPB, et al.Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One, 2014; 9(2):e87572; doi: 10.1371/journal.pone.0087572
5.
KarasavvasN, BillingsE, RaoM, et al.The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses, 2012; 28(11):1444–1457; doi: 10.1089/aid.2012.0103
6.
Zolla-PaznerS, deCampAC, CardozoT, et al.Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One, 2013; 8(1):e53629; doi: 10.1371/journal.pone.0053629
7.
YatesNL, LiaoHX, FongY, et al.Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med, 2014; 6(228):228ra39; doi: 10.1126/scitranslmed.3007730
8.
BonsignoriM, LiaoHX, GaoF, et al.Antibody-virus co-evolution in HIV infection: Paths for HIV vaccine development. Immunol Rev, 2017; 275(1):145–160; doi: 10.1111/imr.12509
9.
HraberP, SeamanMS, BailerRT, et al.Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS, 2014; 28(2):163–169; doi: 10.1097/QAD.0000000000000106
10.
WestAP Jr, DiskinR, NussenzweigMC, et al.Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A, 2012; 109(30):E2083–E2090; doi: 10.1073/pnas.1208984109
11.
WuX, ZhangZ, SchrammCA, et al.Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell, 2015; 161(3):470–485; doi: 10.1016/j.cell.2015.03.004
12.
HootS, McGuireAT, CohenKW, et al.Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog, 2013; 9(1):e1003106; doi: 10.1371/journal.ppat.1003106
13.
AhlersJD. All eyes on the next generation of HIV vaccines: Strategies for inducing a broadly neutralizing antibody response. Discov Med, 2014; 17(94):187–199.
14.
XiaoX, ChenW, FengY, et al.Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun, 2009; 390(3):404–409; doi: 10.1016/j.bbrc.2009.09.029
15.
Havenar-DaughtonC, SarkarA, KulpDW, et al.The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Sci Transl Med, 2018; 10(448); doi: 10.1126/scitranslmed.aat0381
16.
JardineJG, OtaT, SokD, et al.HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science, 2015; 349(6244):156–161; doi: 10.1126/science.aac5894
17.
JardineJ, JulienJP, MenisS, et al.Rational HIV immunogen design to target specific germline B cell receptors. Science, 2013; 340(6133):711–716; doi: 10.1126/science.1234150
BrineyB, SokD, JardineJG, et al.Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies. Cell, 2016; 166(6):1459–1470, e11; doi: 10.1016/j.cell.2016.08.005
20.
AbbottRK, LeeJH, MenisS, et al.Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity, 2018; 48(1):133–146, e6; doi: 10.1016/j.immuni.2017.11.023
21.
HuangD, AbbottRK, Havenar-DaughtonC, et al.B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proc Natl Acad Sci U S A, 2020; 117(37):22920–22931; doi: 10.1073/pnas.2004489117
22.
LinYR, ParksKR, WeidleC, et al.HIV-1 VRC01 germline-targeting immunogens select distinct epitope-specific B cell receptors. Immunity, 2020; 53(4):840–851, e6; doi: 10.1016/j.immuni.2020.09.007
23.
ClinicalTrials.gov. A phase I trial to evaluate the safety and immunogenicity of eOD-GT8 60mer vaccine, adjuvanted. 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT03547245 [Last accessed: June30, 2022].
24.
Ng'uniT, ChasaraC, NdhlovuZM. Major scientific hurdles in HIV vaccine development: Historical perspective and future directions. Front Immunol, 2020; 11:590780; doi: 10.3389/fimmu.2020.590780
25.
Rerks-NgarmS, PitisuttithumP, NitayaphanS, et al.Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361(23):2209–2220; doi: 10.1056/NEJMoa0908492
26.
EdupugantiS, MgodiN, KarunaST, et al.Feasibility and successful enrollment in a proof-of-concept HIV prevention trial of VRC01, a broadly neutralizing HIV-1 monoclonal antibody. J Acquir Immune Defic Syndr, 2021; 87:671–679; doi: 10.1097/QAI.0000000000002639
27.
MgodiNM, TakuvaS, EdupugantiS, et al.A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa: Baseline findings. J Acquir Immune Defic Syndr, 2021; 87:680–687; doi: 10.1097/QAI.0000000000002649
28.
CoreyL, GilbertPB, JuraskaM, et al.Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med, 2021; 384(11):1003–1014; doi: 10.1056/NEJMoa2031738
29.
PlanchaisC, KokA, KanyavuzA, et al.HIV-1 envelope recognition by polyreactive and cross-reactive intestinal B cells. Cell Rep, 2019; 27(2):572–585, e7; doi: 10.1016/j.celrep.2019.03.032
30.
TramaAM, MoodyMA, AlamSM, et al.HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell Host Microbe, 2014; 16(2):215–226; doi: 10.1016/j.chom.2014.07.003
31.
MouquetH, NussenzweigMC. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci, 2012; 69(9):1435–1445; doi: 10.1007/s00018-011-0872-6
32.
WilliamsWB, LiaoHX, MoodyMA, et al.HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science, 2015; 349(6249):aab1253; doi: 10.1126/science.aab1253
33.
MoodyMA, YatesNL, AmosJD, et al.HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol, 2012; 86(14):7496–7507; doi: 10.1128/JVI.00426-12
34.
WieheK, EasterhoffD, LuoK, et al.Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity, 2014; 41(6):909–918; doi: 10.1016/j.immuni.2014.11.014
35.
KrebsSJ, KwonYD, SchrammCA, et al.Longitudinal analysis reveals early development of three MPER-directed neutralizing antibody lineages from an HIV-1-infected individual. Immunity, 2019; 50(3):677–691, e13; doi: 10.1016/j.immuni.2019.02.008
36.
BasuM, PiepenbrinkMS, FrancoisC, et al.Persistence of HIV-1 Env-specific plasmablast lineages in plasma cells after vaccination in humans. Cell Rep Med, 2020; 1(2); doi: 10.1016/j.xcrm.2020.100015
37.
RouphaelNG, MorganC, LiSS, et al.DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest, 2019; 129(11):4769–4785; doi: 10.1172/JCI128699
38.
KobieJJ, AlcenaDC, ZhengB, et al.9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. PLoS One, 2012; 7(4):e35356; doi: 10.1371/journal.pone.0035356
39.
KobieJJ, ZhengB, BrykP, et al.Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther, 2011; 13(6):R209; doi: 10.1186/ar3542
40.
AlamSM, LiaoHX, TomarasGD, et al.Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120N-terminal deletion. J Virol, 2013; 87(3):1554–1568; doi: 10.1128/JVI.00718-12
41.
PiepenbrinkMS, ParkJG, OladunniFS, et al.Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Rep Med, 2021; 2(3):100218; doi: 10.1016/j.xcrm.2021.100218
42.
NogalesA, PiepenbrinkMS, WangJ, et al.A highly potent and broadly neutralizing H1 influenza-specific human monoclonal antibody. Sci Rep, 2018; 8(1):4374; doi: 10.1038/s41598-018-22307-8
43.
TiptonCM, FucileCF, DarceJ, et al.Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol, 2015; 16(7):755–765; doi: 10.1038/ni.3175
44.
AouintiS, GiudicelliV, DurouxP, et al.IMGT/StatClonotype for pairwise evaluation and visualization of NGS IG and TR IMGT clonotype (AA) diversity or expression from IMGT/HighV-QUEST. Front Immunol, 2016; 7(339); doi: 10.3389/fimmu.2016.00339
45.
WuYC, KiplingD, Dunn-WaltersDK. The relationship between CD27 negative and positive B cell populations in human peripheral blood. Front Immunol, 2011; 2:81; doi: 10.3389/fimmu.2011.00081
46.
GhraichyM, GalsonJD, KovaltsukA, et al.Maturation of the human immunoglobulin heavy chain repertoire with age. Front Immunol, 2020; 11:1734; doi: 10.3389/fimmu.2020.01734
47.
OhlinM, ScheepersC, CorcoranM, et al.Inferred allelic variants of immunoglobulin receptor genes: A system for their evaluation, documentation, and naming. Front Immunol, 2019; 10:435; doi: 10.3389/fimmu.2019.00435
48.
GhraichyM, von NiederhausernV, KovaltsukA, et al.Different B cell subpopulations show distinct patterns in their IgH repertoire metrics. Elife, 2021; 10: doi: 10.7554/eLife.73111
49.
ClaireauxM, CanielsTG, de GastM, et al.A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike. bioRxiv, 2021; doi: 10.1101/2021.12.01.470767
50.
HazanovL, MehrR, WuY-CB, et al.Lineage tree analysis of high throughput immunoglobulin sequencing clarifies B cell maturation pathways. International Workshop on Artificial Immune Systems (AIS), Taormina, Italy;, 2015; pp. 1–6; doi: 10.1109/AISW.2015.7469231.
51.
RalphDK, MatsenFA. Likelihood-based inference of B cell clonal families. PLoS Comput Biol, 2016; 12(10):e1005086; doi: 10.1371/journal.pcbi.1005086
52.
FelsensteinJ.PHYLIP (Phylogeny Inference Package) version 3.6. Department of Genome Sciences, University of Washington, Seattle, WA, USA; 2005.
53.
ShannonP, MarkielA, OzierO, et al.Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13(11):2498–2504; doi: 10.1101/gr.1239303
54.
KobieJJ, ZhengB, PiepenbrinkMS, et al.Functional and molecular characteristics of novel and conserved cross-clade HIV envelope specific human monoclonal antibodies. Monoclon Antib Immunodiagn Immunother, 2015; 34(2):65–72; doi: 10.1089/mab.2014.0064
55.
TillerT, MeffreE, YurasovS, et al.Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods, 2008; 329(1–2):112–124; doi: 10.1016/j.jim.2007.09.017
56.
WilliamsWB, HanQ, HaynesBF. Cross-reactivity of HIV vaccine responses and the microbiome. Curr Opin HIV AIDS, 2018; 13(1):9–14; doi: 10.1097/COH.0000000000000423
57.
Zolla-PaznerS, EdlefsenPT, RollandM, et al.Vaccine-induced human antibodies specific for the third variable region of HIV-1 gp120 impose immune pressure on infecting viruses. EBioMedicine, 2014; 1(1):37–45; doi: 10.1016/j.ebiom.2014.10.022
58.
CramJA, Fiore-GartlandAJ, SrinivasanS, et al.Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination. PLoS One, 2019; 14(12):e0225622; doi: 10.1371/journal.pone.0225622
59.
EasterhoffD, MoodyMA, FeraD, et al.Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog, 2017; 13(2):e1006182; doi: 10.1371/journal.ppat.1006182
60.
SotoC, BombardiRG, BranchizioA, et al.High frequency of shared clonotypes in human B cell receptor repertoires. Nature, 2019; 566(7744):398–402; doi: 10.1038/s41586-019-0934-8
61.
SetliffI, McDonnellWJ, RajuN, et al.Multi-donor longitudinal antibody repertoire sequencing reveals the existence of public antibody clonotypes in HIV-1 infection. Cell Host Microbe, 2018; 23(6):845–854, e6; doi: 10.1016/j.chom.2018.05.001
62.
DavisCW, JacksonKJL, McCauslandMM, et al.Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination. Science, 2020; 370(6513):237–241; doi: 10.1126/science.aaz8432
63.
KovacsJM, NkololaJP, PengH, et al.HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A, 2012; 109(30):12111–12116; doi: 10.1073/pnas.1204533109
64.
HeydarchiB, CenterRJ, BebbingtonJ, et al.Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env. MAbs, 2017; 9(3):550–566; doi: 10.1080/19420862.2016.1270491
65.
WilliamsWB, MeyerhoffRR, EdwardsRJ, et al.Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell, 2021; 184(11):2955–2972, e25; doi: 10.1016/j.cell.2021.04.042
66.
YuJS, MaBJ, ScearceRM, et al.Anti-Ebola MAb 17A3 reacts with bovine and human alpha-2-macroglobulin proteins. J Virol Methods, 2010; 168(1–2):248–250; doi: 10.1016/j.jviromet.2010.04.025
67.
ZhuC, DukhovlinovaE, CouncilO, et al.Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies. Nat Commun, 2019; 10(1):948; doi: 10.1038/s41467-019-08876-w
68.
WaghK, HahnBH, KorberB. Hitting the sweet spot: Exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies. Curr Opin HIV AIDS, 2020; 15(5):267–274; doi: 10.1097/COH.0000000000000639
69.
SchorchtA, CottrellCA, PugachP, et al.The glycan hole area of HIV-1 envelope trimers contributes prominently to the induction of autologous neutralization. J Virol, 2022; 96(1):e0155221; doi: 10.1128/JVI.01552-21
70.
GriffithSA, McCoyLE. To bnAb or not to bnAb: Defining broadly neutralising antibodies against HIV-1. Front Immunol, 2021; 12:708227; doi: 10.3389/fimmu.2021.708227
71.
Haji-GhassemiO, BlacklerRJ, Martin YoungN, et al.Antibody recognition of carbohydrate epitopesdagger. Glycobiology, 2015; 25(9):920–952; doi: 10.1093/glycob/cwv037
72.
RuizMJ, GhiglioneY, FaliveneJ, et al.Env-specific IgA from viremic HIV-infected subjects compromises antibody-dependent cellular cytotoxicity. J Virol, 2016; 90(2):670–681; doi: 10.1128/JVI.02363-15
73.
AmosJD, HimesJE, ArmandL, et al.Rapid development of gp120-focused neutralizing B cell responses during acute simian immunodeficiency virus infection of African green monkeys. J Virol, 2015; 89(18):9485–9498; doi: 10.1128/JVI.01564-15
74.
YatesNL, StaceyAR, NolenTL, et al.HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunol, 2013; 6(4):692–703; doi: 10.1038/mi.2012.107
75.
SeatonKE, BallweberL, LanA, et al.HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. PLoS One, 2014; 9(7):e101863; doi: 10.1371/journal.pone.0101863
76.
Granados-GonzalezV, ClaretJ, BerlierW, et al.Opposite immune reactivity of serum IgG and secretory IgA to conformational recombinant proteins mimicking V1/V2 domains of three different HIV type 1 subtypes depending on glycosylation. AIDS Res Hum Retroviruses, 2008; 24(2):289–299; doi: 10.1089/aid.2007.0187
77.
KroeseFG, ButcherEC, StallAM, et al.Many of the IgA producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity. Int Immunol, 1989; 1(1):75–84; doi: 10.1093/intimm/1.1.75
78.
BudeusB, KiblerA, BrauserM, et al.Human cord blood B cells differ from the adult counterpart by conserved Ig repertoires and accelerated response dynamics. J Immunol, 2021; 206:2839–2851; doi: 10.4049/jimmunol.2100113
79.
ShikinaT, HiroiT, IwataniK, et al.IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J Immunol, 2004; 172(10):6259–6264; doi: 10.4049/jimmunol.172.10.6259
80.
BeagleyKW, MurrayAM, McGheeJR, et al.Peritoneal cavity CD5 (Bla) B cells: Cytokine induced IgA secretion and homing to intestinal lamina propria in SCID mice. Immunol Cell Biol, 1995; 73(5):425–432; doi: 10.1038/icb.1995.66
81.
WuX, KongXP. Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Curr Opin Immunol, 2016; 42:56–64; doi: 10.1016/j.coi.2016.05.013
82.
KarrayS, JuompanL, MarounRC, et al.Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J Immunol, 1998; 161(12):6681–6688.
83.
HendersonR, WattsBE, ErginHN, et al.Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. Nat Commun, 2019; 10(1):654; doi: 10.1038/s41467-019-08415-7
84.
ScheidJF, MouquetH, UeberheideB, et al.Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 2011; 333(6049):1633–1637; doi: 10.1126/science.1207227
85.
ZhouJO, ZaidiHA, TonT, et al.The effects of framework mutations at the variable domain interface on antibody affinity maturation in an HIV-1 broadly neutralizing antibody lineage. Front Immunol, 2020; 11:1529; doi: 10.3389/fimmu.2020.01529
86.
ChenF, TzarumN, WilsonIA, et al.VH1-69 antiviral broadly neutralizing antibodies: Genetics, structures, and relevance to rational vaccine design. Curr Opin Virol, 2019; 34:149–159; doi: 10.1016/j.coviro.2019.02.004
87.
KrajP, RaoSP, GlasAM, et al.The human heavy chain Ig V region gene repertoire is biased at all stages of B cell ontogeny, including early pre-B cells. J Immunol, 1997; 158(12):5824–5832.
88.
PappasL, FoglieriniM, PiccoliL, et al.Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature, 2014; 516(7531):418–422; doi: 10.1038/nature13764
89.
LorinV, FernandezI, Masse-RansonG, et al.Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. J Exp Med, 2022; 219(3); doi: 10.1084/jem.20212045
90.
AndrabiR, VossJE, LiangCH, et al.Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity, 2015; 43(5):959–973; doi: 10.1016/j.immuni.2015.10.014
91.
GormanJ, SotoC, YangMM, et al.Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol, 2016; 23(1):81–90; doi: 10.1038/nsmb.3144
92.
XiaoX, ChenW, FengY, et al.Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses, 2009; 1(3):802–817; doi: 10.3390/v1030802
93.
AngelettiD, GibbsJS, AngelM, et al.Defining B cell immunodominance to viruses. Nat Immunol, 2017; 18(4):456–463; doi: 10.1038/ni.3680
94.
LiGM, ChiuC, WrammertJ, et al.Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A, 2012; 109(23):9047–9052; doi: 10.1073/pnas.1118979109
95.
SongG, HeWT, CallaghanS, et al.Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. bioRxiv, 2020; doi: 10.1101/2020.09.22.308965
96.
NgKW, FaulknerN, CornishGH, et al.Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science, 2020; 370(6522):1339–1343; doi: 10.1126/science.abe1107
97.
RogersTF, GoodwinEC, BrineyB, et al.Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. Sci Immunol, 2017; 2(14); doi: 10.1126/sciimmunol.aan6809
98.
ChanKR, WangX, SaronWAA, et al.Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat Microbiol, 2016; 1(12):16164; doi: 10.1038/nmicrobiol.2016.164
99.
JeffriesTL Jr, SachaCR, PollaraJ, et al.The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. Mucosal Immunol, 2016; 9(2):414–427; doi: 10.1038/mi.2015.70
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
